Cytokine release syndrome (immunotherapy)
Immunotherapy · Allergy / Immunology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
A systemic inflammatory response after immune-effector therapies (CAR-T cells, bispecific antibodies, some monoclonal antibodies) with fever, hypotension and hypoxia, ranging from mild to life-threatening.
Red flags
- Hypotension requiring vasopressors
- Hypoxia requiring escalating oxygen
- Neurological changes (ICANS)
- Multi-organ dysfunction
Assessment
Differential diagnosis
- Sepsis
- Anaphylaxis / infusion reaction
- Tumour lysis syndrome
- Immune effector cell-associated neurotoxicity (ICANS)
- Haemophagocytic lymphohistiocytosis
Investigations
- Vital signs and CRS grading (fever, hypotension, hypoxia)
- FBC, U&E, LFTs, CRP, ferritin
- Cultures (concurrent infection common)
- ABG/lactate
- Assess for neurotoxicity (ICANS)
Management
- Recognise and grade CRS; monitor closely
- Provide supportive care: antipyretics, fluids for hypotension, oxygen
- Exclude and treat concurrent infection empirically
- For significant/persistent CRS give tocilizumab (IL-6 receptor blockade)
- Add corticosteroids for tocilizumab-refractory or severe CRS or neurotoxicity
- Escalate to ICU for vasopressor/ventilatory support; involve the treating haematology-oncology team
Drugs & doses
Tocilizumab (IL-6 receptor antagonist) for significant CRS
Corticosteroids for refractory/severe CRS and for neurotoxicity
IV fluids and vasopressors for hypotension
Oxygen; empirical antibiotics if infection cannot be excluded
Disposition
ICU/HDU with the treating cellular therapy/haematology team.
Complications & pitfalls
- Distributive shock
- Respiratory failure
- Neurotoxicity (ICANS)
- Multi-organ failure / HLH-like syndrome
Exam pearls
- Tocilizumab is the specific therapy for CRS; steroids are added for refractory disease and are first-line for the associated neurotoxicity
- CRS and sepsis look identical - treat for infection concurrently
- These patients need a specialist centre familiar with immune-effector toxicities
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.